Susan G. Komen® Announces Nearly $33 Million in New Research Funding to Support Bold Goal of Cutting Breast Cancer Mortality by 50 Percent

Grants Focus on Areas with Greatest Potential to Save Lives

DALLAS–(BUSINESS WIRE)–Building on its bold
goal to reduce current breast cancer deaths by 50 percent in the U.S.
over the next decade
, Susan G. Komen, the world’s leading breast
cancer organization, today announced $32.7 million in new research
grants for 2016. Awarded across 23 states and 7 countries, the projects
span the entire continuum of breast cancer research, including research
into metastatic disease, novel treatments for aggressive types of breast
cancer, new technologies and health equity – areas that will make a
significant impact in achieving the 50 percent goal.


“For nearly 35 years our organization has been a leader in the fight to
end breast cancer, changing how people think about, talk about and treat
this disease. Now, with a sharpened focus on our organization’s new
strategic direction, we are delighted to announce new research funding
that will play a significant role in making our bold goal a reality,”
said Komen President and CEO Judy Salerno, M.D., M.S.

“Not only will these grants accelerate our understanding of key areas in
breast cancer research, but they include funding for early-career
investigators. As federal research dollars become increasingly difficult
to secure, these awards give promising young researchers an opportunity
to establish their careers, and help ensure breakthrough breast cancer
research continues for years to come,” Dr. Salerno added. “Their work is
essential to achieving our vision of a world without breast cancer.”

Grants from Komen’s nearly $33 million 2016 research portfolio* –
including more than $16 million to early-career investigators – will
focus on promising areas in research that have the greatest potential to
save lives, including:

  • 38 grants expanding our knowledge of metastatic breast cancer
    and how to stop it.
  • 15 grants looking into novel treatments for aggressive types of
    breast cancer
    (specifically, triple negative, Luminal B and
    inflammatory breast cancer).
  • 21 grants advancing our ability to detect primary and recurrent
    breast cancer at its earliest stages.
  • 12 grants identifying the causes of breast cancer disparities
    and testing ways to overcome barriers to care.

These new funds bring Komen’s total research investment to more than
$920 million since opening its doors in 1982, the largest of any
nonprofit outside the U.S. government. In addition to research, Komen
and its nationwide network of Affiliates serve women and men in
thousands of communities. To date, more than $2 billion has been
invested in community programs that provide education, screening and
treatment support.

About Susan G. Komen®

Susan G. Komen is the world’s largest breast cancer organization outside
of the federal government, funding more breast cancer research than any
other nonprofit while providing real-time help to those facing the
disease. Since its founding in 1982, Komen has funded more than $920
million in research and provided more than $2 billion in funding to
screening, education, treatment and psychosocial support programs. Komen
has worked in more than 60 countries worldwide. Komen was founded by
Nancy G. Brinker, who promised her sister, Susan G. Komen, that she
would end the disease that claimed Suzy’s life. Visit komen.org
or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social.

*Contingent upon signed and executed contracts with Komen

Contacts

Susan G. Komen
Joni Avery, 972-855-4382
press@komen.org